<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04691804</url>
  </required_header>
  <id_info>
    <org_study_id>SHR3162-III-305</org_study_id>
    <nct_id>NCT04691804</nct_id>
  </id_info>
  <brief_title>A Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line&#xD;
      treatment by assessment of radiographic progression-free survival (rPFS) in mCRPC subjects&#xD;
      unselected for deoxyribonucleic acid (DNA) damage repair deficiencies (DRD) status (Cohort 1)&#xD;
      to evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line&#xD;
      treatment by assessment of rPFS in mCRPC subjects harboring DRD (Cohort 2).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 31, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Fuzuloparib Combined with Abiraterone Acetate and Prednisone (AA-P) versus Placebo Combined with AA-P</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rPFS by blinded independent central review (BICR) using RESIST1.1 and PCWG3</measure>
    <time_frame>up to 3 years</time_frame>
    <description>progression-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>up to 4 years</time_frame>
    <description>time from randomization to death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The percentage of subjects with measureable disease at baseline who achieved a complete or partial response in their soft tissue disease using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA progression</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Time from randomisation to the first time of PSA progression according to the criterion of PCGW3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to skeletal-related events</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Time from randomisation to the first occurrence of a fracture or treatment for the fracture. The skeletal-related event is defined as the occurrence of either pathological or clinical fracture, spinal cord compression, bone-related radiotherapy or surgery.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">804</enrollment>
  <condition>Metastatic Castration-Resistant Prostate Cancer (mCRPC)</condition>
  <arm_group>
    <arm_group_label>Treatment group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fuzuloparib plus AA-P</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fuzuloparib Placebo plus AA-P</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fuzuloparib , Abiraterone acetate and Prednisone</intervention_name>
    <description>Fuzuloparib capsules (strength: 50 mg),150mg, Bid,po&#xD;
Abiraterone acetate tablets (strength: 250 mg) 1000mg Qd,po&#xD;
Prednisone tablets (strength: 5 mg) 5mg, Bid po</description>
    <arm_group_label>Treatment group A</arm_group_label>
    <other_name>SHR3162</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fuzuloparib Placebo， Abiraterone acetate and Prednisone</intervention_name>
    <description>Fuzuloparib capsules Placebo (strength: 50 mg),150mg, Bid,po&#xD;
Abiraterone acetate tablets (strength: 250 mg)1000mg Qd,po&#xD;
Prednisone tablets (strength: 5 mg)5mg, Bid po</description>
    <arm_group_label>Treatment group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Able and willing to provide a written informed consent&#xD;
&#xD;
          2. A score of 0 to 1 for ECOG performance status&#xD;
&#xD;
          3. Age of ≥ 18 years old&#xD;
&#xD;
          4. Prostate adenocarcinoma confirmed&#xD;
&#xD;
          5. Disease progression of metastatic prostate cancer while the subject was on androgen&#xD;
             deprivation therapy.&#xD;
&#xD;
          6. The functional level of the organs must meet the requirements&#xD;
&#xD;
          7. Blood and tumor tissue samples are provided during screening to determine the DRD&#xD;
             status&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Prior treatment with any PARP inhibitor&#xD;
&#xD;
          2. Have received any systemic anti-tumor treatment during the mCRPC stage or&#xD;
             non-metastatic CRPC stage&#xD;
&#xD;
          3. Have used any CYP3A4 inducers or inhibitors within 14 days prior to the first dose&#xD;
&#xD;
          4. Plan to receive any other anti-tumor treatment&#xD;
&#xD;
          5. Presence of radiologically confirmed tumor lesions in the brain&#xD;
&#xD;
          6. Contraindications to the use of Prednisone&#xD;
&#xD;
          7. History of uncontrolled pituitary or adrenal dysfunction&#xD;
&#xD;
          8. Uncontrolled hypertension&#xD;
&#xD;
          9. Presence of active heart diseases&#xD;
&#xD;
         10. Human immunodeficiency virus-positive&#xD;
&#xD;
         11. Presence of dysphagia, chronic diarrhea, intestinal obstruction, or other factors&#xD;
             affecting drug intake and absorption&#xD;
&#xD;
         12. Active HBV or HCV infection&#xD;
&#xD;
         13. Presence of concomitant diseases&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chunlei Jin, M.D</last_name>
    <phone>+86 18036618579</phone>
    <email>jinchunlei@hrglobe.cn</email>
  </overall_contact>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 30, 2020</study_first_submitted>
  <study_first_submitted_qc>December 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

